Novel Gene Therapy Shows Early Promise for Delaying Huntington's Disease

Summary

Latus Bio, a biotechnology company, is developing a new gene therapy for central nervous system disorders, starting with Huntington's disease. Their lead candidate, called LTS-201, relies on a newly designed delivery vehicle. In gene therapy, scientists often use harmless, modified viruses known as adeno-associated viruses, or AAVs, to carry treatments directly into cells. The researchers identified a specific outer shell of the virus, called a capsid, that excels at this task. Named AAV-DB-3, this new capsid successfully delivered genetic material deep into the brain cells of monkeys using just a single, low-dose infusion per brain hemisphere.

Once inside the brain, the therapy works by targeting a specific DNA repair protein called MSH3. In Huntington's disease, certain repeating DNA sequences abnormally expand over time and cause cellular damage. To stop this, the therapy uses an artificial microRNA, which is a tiny molecule specially designed to dial down the production of the MSH3 protein. By lowering the levels of this protein, the researchers aim to reduce these harmful DNA expansions and delay the onset of the disease.

The early results are highly encouraging but still in the laboratory testing phase. In animal studies, the treatment reduced MSH3 levels by 50 percent in specialized mice and by 48 to 94 percent in non-human primates. However, it is important to note that this research is strictly in its preclinical stages and has not yet been tested in humans. The company plans to submit an Investigational New Drug application, a necessary step before human clinical trials can begin, in the second half of 2026.

Why it matters.

For families affected by Huntington's disease, a devastating and currently incurable condition, this research represents an encouraging step forward. Historically, delivering genetic therapies deep into the specific brain networks affected by neurological diseases has been a massive hurdle. By demonstrating that a newly engineered viral shell can effectively reach these elusive targets with a low dose and a single administration, this approach could significantly improve how the industry tackles complex genetic brain disorders.

Furthermore, focusing on the root genetic mechanism offers a fundamentally new way to slow the disease rather than just managing its symptoms. While patients must wait for clinical trials to confirm safety and efficacy in humans, achieving up to a 94 percent reduction of the targeted protein in primates suggests the technology has the potency needed for real impact. If successful, this precision delivery method could eventually pave the way for treating a much wider range of central nervous system conditions.

From the source

The story in numbers.

Series A funding raised by Latus Bio: $97 million
Reduction in MSH3 levels in non-human primates: 48-94%
Drop in MSH3 levels in Q111 HD mouse model at 16 weeks: 50%

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

First inside-the-body CRISPR gene therapy heads to the FDA

Intellia Therapeutics is making medical history as it seeks approval from the US Food and Drug Administration for a groundbreaking genetic treatment. The drug, called lonvoguran ziclumeran or lonvo-z, is the first CRISPR-based gene therapy designed to work "in vivo," meaning the genetic editing happens directly inside the human body. CRISPR is a biological tool that allows scientists to make precise changes to DNA. Intellia is using this technology to treat hereditary angioedema, a genetic condition that causes severe and unpredictable swelling attacks. The company recently completed a Phase 3 clinical trial, which is the final testing step before seeking regulatory approval. In the study, a single dose of lonvo-z reduced swelling attacks by 87 percent compared to a placebo over a six-month period. Even more strikingly, 62 percent of the patients who received the treatment had absolutely no attacks during those six months and were able to completely stop taking their usual preventative medications. While these numbers are highly encouraging, the research does come with a few early caveats. The trial was relatively small, involving a total of 80 patients, with 52 receiving the actual therapy and 28 given a placebo. Additionally, the currently reported results only track the patients for six months. Researchers will need to monitor these individuals for a longer period to confirm that the single dose continues to work safely and effectively over time.

Nature Biotechnology2 min read

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Duchenne muscular dystrophy is a fatal neuromuscular disease caused by a broken or missing muscle protein. Recently, the company Regenxbio announced that its experimental gene therapy produced sufficiently high levels of a miniaturized version of this crucial protein in a clinical trial. By delivering a functional, smaller substitute to patients, the treatment aims to address the root cause of the condition. Following these promising early results, Regenxbio plans to use the clinical trial data to apply for accelerated approval from the Food and Drug Administration. However, we must view these developments with some caution. The initial reports do not disclose the actual size of the clinical trial, the detailed safety profile of the drug, or the exact quantitative protein levels the patients achieved.

STAT News1 min read

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

For decades, doctors have used harmless viruses known as adeno-associated viruses, or AAVs, as biological delivery trucks to treat genetic diseases. These viruses are engineered to carry healthy genes directly into a patient's cells. But a newly published study reveals an unexpected complication. Researchers recently linked a specific brain tumor in a five-year-old boy to an AAV9 gene therapy he received as an infant to treat an inherited disorder called MPS1 deficiency. When the boy was five, doctors discovered a rare neuroepithelial tumor in his brain. By sequencing the genetic material of the mass, scientists found that the gene therapy payload had accidentally woven itself into the boy's own genome. Specifically, the viral delivery cassette fused with a human gene called PLAG1, which is known to drive tumor growth. Curiously, the tumor also contained a stray fragment of a different human chromosome, which researchers suspect was a manufacturing contaminant from when the viral vector was created. Thankfully, the story has a positive outcome so far. Surgeons successfully removed the tumor. Eight months after the operation, the patient shows no signs of the tumor returning and is actually demonstrating advanced cognitive development.

GEN1 min read

Follow your curiosity.

Novel Gene Therapy Shows Early Promise for Delaying Huntington's Disease

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

First inside-the-body CRISPR gene therapy heads to the FDA

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

First inside-the-body CRISPR gene therapy heads to the FDA

Promising Duchenne Gene Therapy Sets Sights on FDA Approval

Gene Therapy Linked to Rare Brain Tumor in a Single Patient

A little science goes a long way.